Olodaterol vs Umeclidinium/Vilanterol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline

Olodaterol

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT00782210 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled phase 3 trial in 624 patients with COPD comparing two doses of olodaterol (5 mcg and 10 mcg once daily) against placebo. Both pre-specified co-primary endpoints—FEV1 AUC 0-3h and trough FEV1 at 12 weeks—were met for both doses, with large, statistically significant differences versus placebo (p<0.0001 for all primary comparisons). The trial was adequately powered, used a regulator-accepted lung function endpoint for COPD, and the primary results were clearly positive.

Reported efficacy

Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) (1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85); Trough FEV1 Response at Day 85 (12 Weeks) (1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.): FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). (met)

Result source: NCT00782210

Umeclidinium/Vilanterol

Marketed by GlaxoSmithKline and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT01777334 · Phase 3 · completed

The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.

Reported efficacy

Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)

Result source: NCT01777334

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlodaterolUmeclidinium/​Vilanterol
Moderate or severe exacerbations, annualised rate0.6 vs 0.7−0.1 vs placebo10 mcg qd · wk 48 · n 234NCT00796653
3 other results
  • 0.7 vs 0.6 10 mcg qd · wk 48 · n 225 · Phase 3 · secondary NCT00793624
  • 0.5 vs 0.7 5 mcg qd · wk 48 · n 232 · Phase 3 · secondary NCT00796653
  • 0.7 vs 0.6 5 mcg qd · wk 48 · n 227 · Phase 3 · secondary NCT00793624
—Trial running · NCT06474039
Trough FEV1, change0.0 vs -0.1+0.1 vs placebo10 mcg qd · wk 24 · n 228NCT00796653
105 other results
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 219 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 202 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 207 · Phase 3 · primary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 24 · n 229 · Phase 3 · primary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 220 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 199 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 205 · Phase 3 · primary NCT00782509
  • 0.2 vs 0.0 5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.0 2.5 μg + 5 μg · wk 12 · n 201 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 2.5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.1 5 μg and 18 μg · wk 12 · n 550 · Phase 3 · primary NCT01696058
  • 0.2 vs 0.1 5µg olodaterol + 18µg tiotropium · wk 12 · n 548 · Phase 3 · primary NCT01694771
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 24 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 18 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 32 · n 202 · Phase 3 · secondary NCT00782210
  • -0.0 vs -0.0 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 40 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 99 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 107 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 10 mcg qd · wk 6 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 90 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 10 mcg qd · wk 2 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 228 · Phase 3 · secondary NCT00796653
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 24 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 32 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 40 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 100 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 115 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 92 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 5 mcg qd · wk 2 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 5 mcg qd · wk 48 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 205 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 48 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00793624
  • 0.2 vs 0.1 2.5/5 · wk 6 · n 214 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 5/5 · wk 6 · n 216 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 2.5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs 0.1 5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs -0.0 10mcg · wk 4 · n 86 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 4 · n 86 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 5mcg · wk 4 · n 79 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 4 · n 80 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 4 · n 79 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 2mcg · wk 4 · n 84 · Phase 2 · primary NCT00824382
  • 0.0 vs -0.0 2 mcg qd · wk 4 · n 81 · Phase 2 · primary NCT00452400
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 10mcg · wk 2 · n 86 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 10 mcg qd · wk 1 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.1 5μg/5μg · wk 4 · n 50 · Phase 4 · secondary NCT04223843
  • 0.2 vs -0.1 5μg/5μg · wk 4 · n 47 · Phase 4 · secondary NCT04223843
  • 0.1 vs -0.0 5mcg · wk 2 · n 79 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 5 mcg qd · wk 1 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 2 · n 79 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 1 · n 79 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • 0.1 vs -0.0 2mcg · wk 2 · n 84 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 2 mcg qd · wk 2 · n 81 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 2 mcg qd · wk 1 · n 81 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.1 vs 0.1 5μg/5μg · wk 12 · n 145 · Phase 4 · secondary NCT03240575
0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446
SGRQ total, change37.1 vs 42.0−4.9 vs placebo5 μg + 5 μg · wk 12 · n 196NCT01964352
22 other results
  • 38.0 vs 42.6 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · primary NCT02006732
  • 37.6 vs 42.3 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · primary NCT02006732
  • 37.9 vs 42.0 2.5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT01964352
  • 38.9 vs 42.6 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · primary NCT02006732
  • 38.4 vs 42.3 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · primary NCT02006732
  • 41.2 vs 43.1 5 μg and 18 μg · wk 12 · n 1039 · Phase 3 · secondary NCT01696058
  • 38.8 vs 39.9 10 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00796653
  • 36.9 vs 40.4 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00793624
  • 38.6 vs 42.1 10 mcg qd · wk 24 · n 212 · Phase 3 · secondary NCT00796653
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00796653
  • 37.7 vs 41.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00793624
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00793624
  • 40.2 vs 42.7 10 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00796653
  • 37.0 vs 42.1 10 mcg qd · wk 12 · n 202 · Phase 3 · secondary NCT00793624
  • 39.6 vs 39.9 5 mcg qd · wk 48 · n 216 · Phase 3 · secondary NCT00796653
  • 38.5 vs 40.4 5 mcg qd · wk 48 · n 200 · Phase 3 · secondary NCT00793624
  • 39.0 vs 42.1 5 mcg qd · wk 24 · n 216 · Phase 3 · secondary NCT00796653
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00796653
  • 38.6 vs 41.1 5 mcg qd · wk 24 · n 200 · Phase 3 · secondary NCT00793624
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00793624
  • 40.1 vs 42.7 5 mcg qd · wk 12 · n 216 · Phase 3 · secondary NCT00796653
  • 39.3 vs 42.1 5 mcg qd · wk 12 · n 200 · Phase 3 · secondary NCT00793624
—Trial running · NCT06474039
TDI focal score1.5 vs 1.1+0.4 vs placebo10 mcg qd · wk 24 · n 220NCT00796653
35 other results
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00796653
  • 2.1 vs 2.0 10 mcg qd · wk 24 · n 207 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 24 · n 221 · Phase 3 · primary NCT00796653
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00796653
  • 2.2 vs 2.0 5 mcg qd · wk 24 · n 212 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00793624
  • 1.8 vs 1.1 10 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00796653
  • 2.3 vs 1.9 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 10 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00796653
  • 1.9 vs 2.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.2 10 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.7 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 10 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00796653
  • 2.1 vs 1.7 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 10 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.4 10 mcg qd · wk 12 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 48 · n 221 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.9 5 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.1 5 mcg qd · wk 40 · n 221 · Phase 3 · secondary NCT00796653
  • 1.8 vs 2.0 5 mcg qd · wk 40 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.2 5 mcg qd · wk 32 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 32 · n 212 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 5 mcg qd · wk 18 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 18 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 5 mcg qd · wk 12 · n 221 · Phase 3 · secondary NCT00796653
  • 1.5 vs 0.3 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · secondary NCT02006732
  • 1.8 vs 1.4 5 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.0 5 mcg qd · wk 6 · n 221 · Phase 3 · secondary NCT00796653
  • 1.6 vs 1.0 5 mcg qd · wk 6 · n 212 · Phase 3 · secondary NCT00793624
  • 1.6 vs 0.3 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · secondary NCT02006732
—Trial running · NCT06474039

Moderate or severe exacerbations, annualised rate

Olodaterol
0.6 vs 0.7−0.1 vs placebo10 mcg qd · wk 48 · n 234NCT00796653
3 other results
  • 0.7 vs 0.6 10 mcg qd · wk 48 · n 225 · Phase 3 · secondary NCT00793624
  • 0.5 vs 0.7 5 mcg qd · wk 48 · n 232 · Phase 3 · secondary NCT00796653
  • 0.7 vs 0.6 5 mcg qd · wk 48 · n 227 · Phase 3 · secondary NCT00793624
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

Trough FEV1, change

Olodaterol
0.0 vs -0.1+0.1 vs placebo10 mcg qd · wk 24 · n 228NCT00796653
105 other results
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 219 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 202 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 207 · Phase 3 · primary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 24 · n 229 · Phase 3 · primary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 220 · Phase 3 · primary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 199 · Phase 3 · primary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 205 · Phase 3 · primary NCT00782509
  • 0.2 vs 0.0 5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.0 2.5 μg + 5 μg · wk 12 · n 201 · Phase 3 · primary NCT01964352
  • 0.2 vs -0.0 2.5 μg + 5 μg · wk 12 · n 200 · Phase 3 · primary NCT02006732
  • 0.2 vs 0.1 5 μg and 18 μg · wk 12 · n 550 · Phase 3 · primary NCT01696058
  • 0.2 vs 0.1 5µg olodaterol + 18µg tiotropium · wk 12 · n 548 · Phase 3 · primary NCT01694771
  • 0.0 vs -0.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 24 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 18 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 18 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 32 · n 202 · Phase 3 · secondary NCT00782210
  • -0.0 vs -0.0 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 32 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 12 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 12 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 10 mcg qd · wk 40 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 228 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 10 mcg qd · wk 40 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 6 · n 99 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 107 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 10 mcg qd · wk 6 · n 219 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 10 mcg qd · wk 6 · n 90 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 202 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 10 mcg qd · wk 2 · n 207 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 228 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 228 · Phase 3 · secondary NCT00796653
  • -0.0 vs -0.1 10 mcg qd · wk 48 · n 219 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 24 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 24 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 18 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 32 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.0 5 mcg qd · wk 12 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.1 5 mcg qd · wk 40 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.0 5 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 205 · Phase 3 · secondary NCT00782509
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 6 · n 100 · Phase 3 · secondary NCT01040689
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 115 · Phase 3 · secondary NCT01040728
  • 0.0 vs -0.0 5 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00793624
  • 0.1 vs 0.0 5 mcg qd · wk 6 · n 92 · Phase 3 · secondary NCT00932646
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 199 · Phase 3 · secondary NCT00782210
  • 0.1 vs 0.0 5 mcg qd · wk 2 · n 205 · Phase 3 · secondary NCT00782509
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 229 · Phase 3 · secondary NCT00796653
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 220 · Phase 3 · secondary NCT00793624
  • 0.0 vs -0.7 5 mcg qd · wk 48 · n 199 · Phase 3 · secondary NCT00782210
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 205 · Phase 3 · secondary NCT00782509
  • -0.0 vs -0.1 5 mcg qd · wk 48 · n 229 · Phase 3 · secondary NCT00796653
  • 0.0 vs -0.1 5 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00793624
  • 0.2 vs 0.1 2.5/5 · wk 6 · n 214 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 5/5 · wk 6 · n 216 · Phase 3 · secondary NCT01969721
  • 0.2 vs 0.1 2.5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs 0.1 5 / 5 μg · wk 52 · n 39 · Phase 3 · secondary NCT01536262
  • 0.1 vs -0.0 10mcg · wk 4 · n 86 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 4 · n 86 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 5mcg · wk 4 · n 79 · Phase 2 · primary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 4 · n 80 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 4 · n 79 · Phase 2 · primary NCT00452400
  • 0.1 vs -0.0 2mcg · wk 4 · n 84 · Phase 2 · primary NCT00824382
  • 0.0 vs -0.0 2 mcg qd · wk 4 · n 81 · Phase 2 · primary NCT00452400
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 10mcg · wk 2 · n 86 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 10 mcg qd · wk 2 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 10 mcg qd · wk 1 · n 86 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.1 5μg/5μg · wk 4 · n 50 · Phase 4 · secondary NCT04223843
  • 0.2 vs -0.1 5μg/5μg · wk 4 · n 47 · Phase 4 · secondary NCT04223843
  • 0.1 vs -0.0 5mcg · wk 2 · n 79 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 5 mcg qd · wk 2 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 5 mcg qd · wk 1 · n 80 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 2 · n 79 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 20 mcg qd · wk 1 · n 79 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 6 mg · wk 0.4286 · n 73 · Phase 2 · secondary NCT03673670
  • 0.1 vs -0.0 2mcg · wk 2 · n 84 · Phase 2 · secondary NCT00824382
  • 0.1 vs -0.0 2 mcg qd · wk 2 · n 81 · Phase 2 · secondary NCT00452400
  • 0.1 vs -0.0 2 mcg qd · wk 1 · n 81 · Phase 2 · secondary NCT00452400
  • 0.2 vs 0.1 1.5 mg · wk 0.4286 · n 74 · Phase 2 · secondary NCT03673670
  • 0.1 vs 0.1 5μg/5μg · wk 12 · n 145 · Phase 4 · secondary NCT03240575
Umeclidinium/​Vilanterol
0.2 vs 0.1vs TIO62.5/25 µg · wk 24 · n 400NCT01777334
3 other results
  • 0.1 vs -0.0 62.5/25 µg · wk 12.14 · n 224 · Phase 3 · primary NCT01899742
  • 0.2 vs 0.2 wk 12 · n 309 · Phase 3 · secondary NCT02487446
  • 0.2 vs 0.2 wk 12 · n 314 · Phase 3 · secondary NCT02487446

SGRQ total, change

Olodaterol
37.1 vs 42.0−4.9 vs placebo5 μg + 5 μg · wk 12 · n 196NCT01964352
22 other results
  • 38.0 vs 42.6 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · primary NCT02006732
  • 37.6 vs 42.3 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · primary NCT02006732
  • 37.9 vs 42.0 2.5 μg + 5 μg · wk 12 · n 199 · Phase 3 · primary NCT01964352
  • 38.9 vs 42.6 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · primary NCT02006732
  • 38.4 vs 42.3 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · primary NCT02006732
  • 41.2 vs 43.1 5 μg and 18 μg · wk 12 · n 1039 · Phase 3 · secondary NCT01696058
  • 38.8 vs 39.9 10 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00796653
  • 36.9 vs 40.4 10 mcg qd · wk 48 · n 202 · Phase 3 · secondary NCT00793624
  • 38.6 vs 42.1 10 mcg qd · wk 24 · n 212 · Phase 3 · secondary NCT00796653
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00796653
  • 37.7 vs 41.1 10 mcg qd · wk 24 · n 202 · Phase 3 · secondary NCT00793624
  • 38.2 vs 41.6 10 mcg qd · wk 24 · n 414 · Phase 3 · secondary NCT00793624
  • 40.2 vs 42.7 10 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00796653
  • 37.0 vs 42.1 10 mcg qd · wk 12 · n 202 · Phase 3 · secondary NCT00793624
  • 39.6 vs 39.9 5 mcg qd · wk 48 · n 216 · Phase 3 · secondary NCT00796653
  • 38.5 vs 40.4 5 mcg qd · wk 48 · n 200 · Phase 3 · secondary NCT00793624
  • 39.0 vs 42.1 5 mcg qd · wk 24 · n 216 · Phase 3 · secondary NCT00796653
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00796653
  • 38.6 vs 41.1 5 mcg qd · wk 24 · n 200 · Phase 3 · secondary NCT00793624
  • 38.8 vs 41.6 5 mcg qd · wk 24 · n 416 · Phase 3 · secondary NCT00793624
  • 40.1 vs 42.7 5 mcg qd · wk 12 · n 216 · Phase 3 · secondary NCT00796653
  • 39.3 vs 42.1 5 mcg qd · wk 12 · n 200 · Phase 3 · secondary NCT00793624
Umeclidinium/​Vilanterol
—Trial running · NCT06474039

TDI focal score

Olodaterol
1.5 vs 1.1+0.4 vs placebo10 mcg qd · wk 24 · n 220NCT00796653
35 other results
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00796653
  • 2.1 vs 2.0 10 mcg qd · wk 24 · n 207 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 10 mcg qd · wk 24 · n 427 · Phase 3 · primary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 24 · n 221 · Phase 3 · primary NCT00796653
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00796653
  • 2.2 vs 2.0 5 mcg qd · wk 24 · n 212 · Phase 3 · primary NCT00793624
  • 2.0 vs 1.5 5 mcg qd · wk 24 · n 433 · Phase 3 · primary NCT00793624
  • 1.8 vs 1.1 10 mcg qd · wk 48 · n 220 · Phase 3 · secondary NCT00796653
  • 2.3 vs 1.9 10 mcg qd · wk 48 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 10 mcg qd · wk 40 · n 220 · Phase 3 · secondary NCT00796653
  • 1.9 vs 2.0 10 mcg qd · wk 40 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.2 10 mcg qd · wk 32 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.7 10 mcg qd · wk 32 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 10 mcg qd · wk 18 · n 220 · Phase 3 · secondary NCT00796653
  • 2.1 vs 1.7 10 mcg qd · wk 18 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 10 mcg qd · wk 12 · n 220 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.4 10 mcg qd · wk 12 · n 207 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 220 · Phase 3 · secondary NCT00796653
  • 1.7 vs 1.0 10 mcg qd · wk 6 · n 207 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.1 5 mcg qd · wk 48 · n 221 · Phase 3 · secondary NCT00796653
  • 2.0 vs 1.9 5 mcg qd · wk 48 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.1 5 mcg qd · wk 40 · n 221 · Phase 3 · secondary NCT00796653
  • 1.8 vs 2.0 5 mcg qd · wk 40 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.2 5 mcg qd · wk 32 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 32 · n 212 · Phase 3 · secondary NCT00793624
  • 1.5 vs 1.0 5 mcg qd · wk 18 · n 221 · Phase 3 · secondary NCT00796653
  • 1.9 vs 1.7 5 mcg qd · wk 18 · n 212 · Phase 3 · secondary NCT00793624
  • 1.7 vs 1.1 5 mcg qd · wk 12 · n 221 · Phase 3 · secondary NCT00796653
  • 1.5 vs 0.3 5 μg + 5 μg · wk 12 · n 197 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 5 μg + 5 μg · wk 12 · n 393 · Phase 3 · secondary NCT02006732
  • 1.8 vs 1.4 5 mcg qd · wk 12 · n 212 · Phase 3 · secondary NCT00793624
  • 1.4 vs 1.0 5 mcg qd · wk 6 · n 221 · Phase 3 · secondary NCT00796653
  • 1.6 vs 1.0 5 mcg qd · wk 6 · n 212 · Phase 3 · secondary NCT00793624
  • 1.6 vs 0.3 2.5 μg + 5 μg · wk 12 · n 195 · Phase 3 · secondary NCT02006732
  • 1.7 vs 0.1 2.5 μg + 5 μg · wk 12 · n 394 · Phase 3 · secondary NCT02006732
Umeclidinium/​Vilanterol
—Trial running · NCT06474039
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Olodaterol: 7 of 7 rows · Umeclidinium/Vilanterol: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlodaterol
Rows use multiple source trials
Umeclidinium/​Vilanterol
Rows use multiple source trials
FEV1 AUC 12-24h
absolute change · L
0.16 vs 0.132 F+S 250/50 L @ 6wk2.5/5a,b,c,d
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
0.172 vs 0.132 F+S 250/50 L @ 6wk5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
0.2076 vs 0.2025 Umeclidinium/Vilanterol L @ 12wkb,c,d
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC(0-24h
absolute change · L
NA vs 0.122 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μga,e,b,c
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.174 vs 0.122 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wka,e,b,c
NCT02487446 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk
NCT02487446 · Phase 3 · registry result, not featured evidence
FEV1 AUC0-12h
absolute change · L
0.139 vs -0.029 placebo L @ 12wk10 mcg qda,b,c
NCT00782210 · Phase 3
show 1 more dose
0.144 vs -0.029 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.2543 vs 0.2848 Umeclidinium/Vilanterol L @ 12wkb,c
NCT02487446 · Phase 3 · registry result, not featured evidence
Dropout rate
—10 mcgf
NCT00782210 · Phase 3
show 77 more results
16.9%10 mcg qd
NCT00782210 · Phase 3
—5 mcg
NCT00782210 · Phase 3
16.8%5 mcg qd
NCT00782210 · Phase 3
—10 mcg
NCT00782509 · Phase 3
16.6%10 mcg qd
NCT00782509 · Phase 3
—5 mcg
NCT00782509 · Phase 3
11.5%5 mcg qd
NCT00782509 · Phase 3
15.4%10 mcg qd
NCT00796653 · Phase 3
15.9%5 mcg qd
NCT00796653 · Phase 3
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
1.4%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
0%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
—5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
13.2%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
6.6%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
—2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
—5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
3.9%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
3%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
4.5%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
7.6%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
5.3%2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
4.3%5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
5%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
4.9%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.1%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
17.3%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
15.9%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
5.8%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
3.8%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
2.4%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
8.8%5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
3.8%20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
11.7%62.5/25 µgg
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
6.9%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—10 mcgf
NCT00782210 · Phase 3
show 77 more results
7.7%10 mcg qd
NCT00782210 · Phase 3
—5 mcg
NCT00782210 · Phase 3
8.2%5 mcg qd
NCT00782210 · Phase 3
—10 mcg
NCT00782509 · Phase 3
9.2%10 mcg qd
NCT00782509 · Phase 3
—5 mcg
NCT00782509 · Phase 3
4.8%5 mcg qd
NCT00782509 · Phase 3
6.8%10 mcg qd
NCT00796653 · Phase 3
6.9%5 mcg qd
NCT00796653 · Phase 3
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
0%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
—5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
6.6%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
5.3%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
—2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
—5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
1.5%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
1%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
3.7%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
5.3%2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
3.6%5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.5%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
4.9%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
3.2%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
6.7%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
7%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
—10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
—6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
—
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.7%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.3%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.2%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
—2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
—10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
0%10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
6.3%5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
1.2%2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
4%62.5/25 µgg
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
—62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—
NCT02487446 · Phase 3 · registry result, not featured evidence
—27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Serious AEs
20.8%10 mcgf
NCT00782210 · Phase 3
show 77 more results
—10 mcg qd
NCT00782210 · Phase 3
18.8%5 mcg
NCT00782210 · Phase 3
—5 mcg qd
NCT00782210 · Phase 3
17.1%10 mcg
NCT00782509 · Phase 3
—10 mcg qd
NCT00782509 · Phase 3
15.3%5 mcg
NCT00782509 · Phase 3
—5 mcg qd
NCT00782509 · Phase 3
17.5%10 mcg qd
NCT00796653 · Phase 3
14.7%5 mcg qd
NCT00796653 · Phase 3
1.9%5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT04223843 · Phase 4 · registry result, not featured evidence · combination
3.9%5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
—5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
4.8%5/5 μg
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
1.8%5/5 mcg
NCT02683109 · Phase 4 · registry result, not featured evidence
3.9%5/5
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
10.5%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
3.9%5/5 μg
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
2.8%2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
3.2%5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
4.9%5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
—5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
3%5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2%2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
—2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
4.2%5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
—2.5 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
—5.0 / 5.0 µg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.9%5.0 / 5.0 μg
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
15%2.5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.3%5 / 5 μg
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
7.1%5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
2.1%10 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
2%5 mcg
NCT01040130 · Phase 3 · registry result, not featured evidence
2%10 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
5.3%5 mcg
NCT01040793 · Phase 3 · registry result, not featured evidence
0%10 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
1%5 mcg
NCT01040689 · Phase 3 · registry result, not featured evidence
7.1%10 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
2.6%5 mcg
NCT01040728 · Phase 3 · registry result, not featured evidence
11.6%10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
14.5%5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3.2%10 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
4.3%5 mcg
NCT00932646 · Phase 3 · registry result, not featured evidence
1.4%6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0%1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
3.5%10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
1.3%5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
3.6%2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0%10 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5 mcg qd
NCT00846768 · Phase 2 · registry result, not featured evidence
2.1%2 mcg Bid
NCT00846768 · Phase 2 · registry result, not featured evidence
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.3%10 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%5 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%20 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
2.5%2 mcg
NCT00452400 · Phase 2 · registry result, not featured evidence
—2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
3.5%62.5/25 µgg
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.8%
NCT02487446 · Phase 3 · registry result, not featured evidence
5%27.5/12.5 Bid
NCT02487498 · Phase 3 · registry result, not featured evidence
2.8%62.5/25 µg
NCT01899742 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
10 mcgf
chronic obstructive pulmonary disease 23.7% (placebo 27.3%)
nasopharyngitis 6.3% (placebo 6.2%)
upper respiratory tract infection 6.3% (placebo 7.2%)
NCT00782210 · Phase 3
show 57 more results
5 mcg
chronic obstructive pulmonary disease 19.2% (placebo 27.3%)
nasopharyngitis 10.1% (placebo 6.2%)
upper respiratory tract infection 10.1% (placebo 7.2%)
NCT00782210 · Phase 3
10 mcg
chronic obstructive pulmonary disease 21.7% (placebo 19.9%)
nasopharyngitis 11.5% (placebo 8.3%)
upper respiratory tract infection 10.1% (placebo 7.9%)
NCT00782509 · Phase 3
5 mcg
chronic obstructive pulmonary disease 18.7% (placebo 19.9%)
upper respiratory tract infection 9.6% (placebo 7.9%)
nasopharyngitis 9.1% (placebo 8.3%)
NCT00782509 · Phase 3
10 mcg qd
chronic obstructive pulmonary disease 20.5% (placebo 21.7%)
nasopharyngitis 12% (placebo 9.4%)
upper respiratory tract infection 6.4% (placebo 7.7%)
NCT00796653 · Phase 3
5 mcg qd
chronic obstructive pulmonary disease 17.2% (placebo 21.7%)
nasopharyngitis 15.5% (placebo 9.4%)
upper respiratory tract infection 6% (placebo 7.7%)
NCT00796653 · Phase 3
5μg/5μg
chronic obstructive pulmonary disease 5.3%
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 13.3%
viral upper respiratory tract infection 13.3%
cough 4.8%
NCT02853123 · Phase 4 · registry result, not featured evidence · combination
5/5 mcg
chronic obstructive pulmonary disease 8.1%
NCT02683109 · Phase 4 · registry result, not featured evidence
5/5
viral upper respiratory tract infection 10%
NCT02629965 · Phase 3 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 17.1% (placebo 21.3%)
nasopharyngitis 13.2% (placebo 10.7%)
dyspnoea 2.6% (placebo 2.7%)
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
5/5 μg
chronic obstructive pulmonary disease 15.8% (placebo 21.3%)
nasopharyngitis 5.3% (placebo 10.7%)
back pain 2.6% (placebo 5.3%)
NCT02085161 · Phase 3 · registry result, not featured evidence · combination
2.5/5
nasopharyngitis 5.6%
chronic obstructive pulmonary disease 4.7%
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
5/5
chronic obstructive pulmonary disease 8.1%
nasopharyngitis 5.4%
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
5 μg + 5 μg
chronic obstructive pulmonary disease 4.4% (placebo 9.8%)
nasopharyngitis 3.4% (placebo 5.9%)
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
2.5 μg + 5 μg
chronic obstructive pulmonary disease 7.9% (placebo 9.8%)
nasopharyngitis 4.5% (placebo 5.9%)
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
5 μg + 5 μg
chronic obstructive pulmonary disease 4.5% (placebo 6.9%)
cough 1.5% (placebo 5.9%)
dyspnoea 1% (placebo 6.9%)
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
2.5 μg + 5 μg
chronic obstructive pulmonary disease 8.4% (placebo 6.9%)
cough 2.5% (placebo 5.9%)
dyspnoea 2% (placebo 6.9%)
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
5 μg and 18 μg
chronic obstructive pulmonary disease 8.5% (placebo 7.7%)
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
2.5 / 5.0 μg
chronic obstructive pulmonary disease 7.5% (placebo 11.4%)
cough 6.8% (placebo 6.1%)
nasopharyngitis 6.8% (placebo 4.5%)
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
5.0 / 5.0 μg
chronic obstructive pulmonary disease 7.2% (placebo 11.4%)
nasopharyngitis 2.9% (placebo 4.5%)
cough 1.4% (placebo 6.1%)
NCT01525615 · Phase 3 · registry result, not featured evidence · combination
2.5 / 5 μg
nasopharyngitis 27.5%
bronchitis 12.5%
chronic obstructive pulmonary disease 10%
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
5 / 5 μg
nasopharyngitis 26.8%
chronic obstructive pulmonary disease 17.1%
bronchitis 14.6%
NCT01536262 · Phase 3 · registry result, not featured evidence · combination
5µg olodaterol + 18µg tiotropium
chronic obstructive pulmonary disease 10.6%
NCT01694771 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 3.5% (placebo 5.6%)
NCT01040130 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 6.8% (placebo 5.6%)
NCT01040130 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 2.7% (placebo 6%)
NCT01040793 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 5.3% (placebo 6%)
NCT01040793 · Phase 3 · registry result, not featured evidence
10 mcg
nasopharyngitis 4% (placebo 7.8%)
chronic obstructive pulmonary disease 2% (placebo 3.9%)
NCT01040689 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 7.9% (placebo 3.9%)
nasopharyngitis 5.9% (placebo 7.8%)
NCT01040689 · Phase 3 · registry result, not featured evidence
10 mcg
nasopharyngitis 3.5% (placebo 3.7%)
chronic obstructive pulmonary disease 2.7% (placebo 3.7%)
NCT01040728 · Phase 3 · registry result, not featured evidence
5 mcg
nasopharyngitis 7% (placebo 3.7%)
chronic obstructive pulmonary disease 5.2% (placebo 3.7%)
NCT01040728 · Phase 3 · registry result, not featured evidence
10 mcg qd
chronic obstructive pulmonary disease 27.6% (placebo 22.7%)
nasopharyngitis 11.1% (placebo 6.7%)
cough 5.8% (placebo 3.1%)
NCT00793624 · Phase 3 · registry result, not featured evidence
5 mcg qd
chronic obstructive pulmonary disease 29.5% (placebo 22.7%)
nasopharyngitis 9.7% (placebo 6.7%)
upper respiratory tract infection 7.5% (placebo 6.7%)
NCT00793624 · Phase 3 · registry result, not featured evidence
10 mcg
chronic obstructive pulmonary disease 7.4% (placebo 5.3%)
upper respiratory tract infection 5.3% (placebo 4.3%)
NCT00932646 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 5.4% (placebo 5.3%)
upper respiratory tract infection 4.3% (placebo 4.3%)
NCT00932646 · Phase 3 · registry result, not featured evidence
6 mg
headache 6.8% (placebo 1.3%)
ventricular extrasystoles 4.1% (placebo 0%)
chronic obstructive pulmonary disease 2.7% (placebo 1.3%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
1.5 mg
headache 6.7% (placebo 1.3%)
ventricular extrasystoles 2.7% (placebo 0%)
accelerated idioventricular rhythm 1.3% (placebo 0%)
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
nasopharyngitis 1.9% (placebo 5.7%)
NCT02030535 · Phase 2 · registry result, not featured evidence · combination
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
10mcg
nasopharyngitis 5.8% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
5mcg
nasopharyngitis 3.8% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
2mcg
nasopharyngitis 10.7% (placebo 3.8%)
myalgia 0% (placebo 5.1%)
NCT00824382 · Phase 2 · registry result, not featured evidence
10 mcg qd
nasopharyngitis 6.5%
dyspnoea 0%
NCT00846768 · Phase 2 · registry result, not featured evidence
5 mcg Bid
nasopharyngitis 6.5%
dyspnoea 2.2%
NCT00846768 · Phase 2 · registry result, not featured evidence
5 mcg qd
dyspnoea 6.4%
nasopharyngitis 2.1%
NCT00846768 · Phase 2 · registry result, not featured evidence
2 mcg Bid
nasopharyngitis 2.1%
dyspnoea 0%
NCT00846768 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 4.7% (placebo 1.3%)
headache 3.5% (placebo 5.1%)
cough 2.3% (placebo 2.5%)
NCT00452400 · Phase 2 · registry result, not featured evidence
5 mcg
cough 7.5% (placebo 2.5%)
nasopharyngitis 7.5% (placebo 1.3%)
dyspnoea 2.5% (placebo 7.6%)
NCT00452400 · Phase 2 · registry result, not featured evidence
20 mcg
dyspnoea 3.8% (placebo 7.6%)
cough 2.5% (placebo 2.5%)
nasopharyngitis 2.5% (placebo 1.3%)
NCT00452400 · Phase 2 · registry result, not featured evidence
2 mcg
cough 4.9% (placebo 2.5%)
dyspnoea 3.7% (placebo 7.6%)
headache 3.7% (placebo 5.1%)
NCT00452400 · Phase 2 · registry result, not featured evidence
62.5/25 µgg
headache 8.8%
nasopharyngitis 6.2%
cough 2.9%
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 5 more results
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 10.6%
nasopharyngitis 5.6%
oropharyngeal pain 2.9%
NCT02487446 · Phase 3 · registry result, not featured evidence
27.5/12.5 Bid
chronic obstructive pulmonary disease 14.8%
bronchitis 3.3%
sinusitis 1.8%
NCT02487498 · Phase 3 · registry result, not featured evidence
62.5/25 µg
nasopharyngitis 7.3%
headache 6.5%
NCT01899742 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 6 weeks versus 12 weeks.
  5. eTrial phases differ: Phase 4 versus Phase 3.
  6. fPopulation comparability has not been reviewed for these studies.
  7. gPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olodaterol

FEV1 AUC0-3 0.169 vs -0.007 placebo L @ 12wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 68 more results
0.199 vs 0.024 placebo L @ 0wk10 mcg qd
NCT00782210 · Phase 3
0.192 vs 0 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.165 vs -0.001 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.143 vs -0.18 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.126 vs -0.043 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.152 vs 0.008 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.196 vs 0.025 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.177 vs 0.025 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.171 vs 0.01 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.126 vs -0.01 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.128 vs -0.03 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.14 vs -0.013 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.214 vs 0.021 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.181 vs -0.01 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.167 vs -0.008 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.116 vs -0.025 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.191 vs -0.021 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.17 vs -0.045 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.256 vs 0.018 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.255 vs 0.011 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.156 vs -0.009 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.181 vs 0.015 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.161 vs 0.001 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.167 vs -0.003 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.123 vs -0.023 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.202 vs 0.004 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.173 vs -0.02 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.236 vs 0.031 placebo L @ 0wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.218 vs 0 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.209 vs 0.006 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.165 vs -0.007 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.189 vs 0.024 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.18 vs 0 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.169 vs -0.001 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.156 vs -0.18 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.13 vs -0.043 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.159 vs 0.008 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.189 vs 0.025 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.188 vs 0.025 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.18 vs 0.01 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.155 vs -0.01 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.132 vs -0.03 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.116 vs -0.013 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.181 vs 0.021 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.162 vs -0.01 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.138 vs -0.008 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.093 vs -0.025 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.161 vs -0.021 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.161 vs -0.045 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.232 vs 0.018 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.225 vs 0.011 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.142 vs -0.009 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.201 vs 0.015 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.178 vs 0.001 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.176 vs -0.003 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.122 vs -0.023 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.19 vs 0.004 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.177 vs -0.02 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.203 vs 0.031 placebo L @ 0wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.215 vs 0 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.2 vs 0.006 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.234 vs 0.031 placebo L @ 0wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.247 vs 0 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.211 vs 0.006 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.118 vs -0.02 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.165 vs 0.031 placebo L @ 0wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.186 vs 0 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.166 vs 0.006 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FEV1 Peak 0.275 vs 0.104 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 84 more results
0.267 vs 0.077 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.238 vs 0.066 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.236 vs 0.071 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.206 vs 0.055 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.192 vs 0.029 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.276 vs 0.099 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.251 vs 0.104 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.246 vs 0.08 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.217 vs 0.088 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.197 vs 0.062 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.198 vs 0.041 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.278 vs 0.099 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.248 vs 0.066 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.232 vs 0.064 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.211 vs 0.06 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.178 vs 0.052 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.279 vs 0.04 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.253 vs 0.019 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.342 vs 0.076 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.325 vs 0.082 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.25 vs 0.1 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.234 vs 0.081 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.241 vs 0.082 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.225 vs 0.068 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.193 vs 0.053 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.273 vs 0.076 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.22 vs 0.025 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.295 vs 0.078 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.335 vs 0.104 placebo L @ 0wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.295 vs 0.062 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.282 vs 0.079 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.259 vs 0.104 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.254 vs 0.077 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.238 vs 0.066 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.235 vs 0.071 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.23 vs 0.055 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.198 vs 0.029 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.267 vs 0.099 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.259 vs 0.104 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.252 vs 0.08 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.232 vs 0.088 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.226 vs 0.062 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.197 vs 0.041 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.26 vs 0.099 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.235 vs 0.066 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.206 vs 0.064 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.183 vs 0.06 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.163 vs 0.052 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.341 vs 0.243 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
NA vs 0.243 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg
NCT03240575 · Phase 4 · registry result, not featured evidence · combination
0.389 vs 0.27 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.253 vs 0.04 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.232 vs 0.019 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.313 vs 0.076 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.29 vs 0.082 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.277 vs 0.1 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.248 vs 0.081 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.247 vs 0.082 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.216 vs 0.068 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.192 vs 0.053 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.268 vs 0.076 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.227 vs 0.025 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.247 vs 0.078 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.288 vs 0.104 placebo L @ 0wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.293 vs 0.062 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.267 vs 0.079 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.303 vs 0.078 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.335 vs 0.104 placebo L @ 0wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.321 vs 0.062 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.28 vs 0.079 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.506 vs 0.519 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.467 vs 0.445 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.405 vs 0.324 placebo L6 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.371 vs 0.271 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.17 vs 0.025 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.242 vs 0.078 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.259 vs 0.104 placebo L @ 0wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.264 vs 0.062 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.243 vs 0.079 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.565 vs 0.519 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.49 vs 0.445 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.453 vs 0.324 placebo L1.5 mg
NCT03673670 · Phase 2 · registry result, not featured evidence · combination
0.401 vs 0.291 F+S 250/50 L @ 6wk2.5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
0.432 vs 0.291 F+S 250/50 L @ 6wk5/5
NCT01969721 · Phase 3 · registry result, not featured evidence · combination
FVC AUC(0-3 0.392 vs 0.063 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 59 more results
0.353 vs 0.026 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.316 vs 0.022 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.295 vs 0.003 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.281 vs 0.026 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.231 vs -0.04 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.384 vs 0.052 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.323 vs 0.096 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.294 vs 0.048 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.291 vs 0.046 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.281 vs 0.062 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.271 vs 0.053 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.332 vs 0.082 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.276 vs 0.027 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.253 vs 0.006 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.225 vs 0.012 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.201 vs -0.036 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.288 vs -0.024 placebo L10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.235 vs -0.083 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.419 vs 0.053 placebo L10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.397 vs 0.044 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.311 vs 0.076 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.265 vs 0.016 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.278 vs 0.023 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.252 vs 0.037 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.219 vs 0.016 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.237 vs 0.004 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.35 vs 0.063 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.323 vs 0.026 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.276 vs 0.022 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.277 vs 0.003 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.261 vs 0.026 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.204 vs -0.04 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.383 vs 0.052 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.338 vs 0.096 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.312 vs 0.048 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.284 vs 0.046 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.303 vs 0.062 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.271 vs 0.053 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.312 vs 0.082 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.277 vs 0.027 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.235 vs 0.006 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.212 vs 0.012 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.182 vs -0.036 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.446 vs -0.011 placebo L @ 12wk5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.414 vs -0.018 placebo L @ 12wk5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.244 vs -0.024 placebo L5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.234 vs -0.083 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.423 vs 0.053 placebo L5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.388 vs 0.044 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.299 vs 0.076 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.252 vs 0.016 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.233 vs 0.023 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.22 vs 0.037 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.196 vs 0.016 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.254 vs 0.004 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.387 vs -0.011 placebo L @ 12wk2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.436 vs -0.018 placebo L @ 12wk2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.424 vs 0.306 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.257 vs 0.004 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
FVC Trough 0.169 vs -0.015 placebo L @ 2wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 90 more results
0.135 vs -0.005 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.13 vs -0.03 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.134 vs -0.028 placebo L @ 18wk10 mcg qd
NCT00782210 · Phase 3
0.096 vs -0.028 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.097 vs -0.026 placebo L @ 32wk10 mcg qd
NCT00782210 · Phase 3
0.111 vs -0.044 placebo L @ 40wk10 mcg qd
NCT00782210 · Phase 3
0.032 vs -0.083 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.141 vs 0.054 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.147 vs 0.029 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.091 vs 0.043 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.098 vs 0.064 placebo L @ 18wk10 mcg qd
NCT00782509 · Phase 3
0.091 vs 0.021 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.058 vs 0.061 placebo L @ 32wk10 mcg qd
NCT00782509 · Phase 3
0.131 vs 0.062 placebo L @ 40wk10 mcg qd
NCT00782509 · Phase 3
0.054 vs -0.008 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.173 vs 0.03 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.101 vs -0.014 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.062 vs -0.041 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.107 vs -0.014 placebo L @ 18wk10 mcg qd
NCT00796653 · Phase 3
0.019 vs -0.044 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.063 vs -0.007 placebo L @ 32wk10 mcg qd
NCT00796653 · Phase 3
0.105 vs -0.016 placebo L @ 40wk10 mcg qd
NCT00796653 · Phase 3
0.032 vs -0.069 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.13 vs -0.082 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.215 vs -0.001 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.119 vs 0.042 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.085 vs -0.046 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.087 vs -0.018 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.078 vs 0.06 placebo L @ 18wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.064 vs -0.018 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.084 vs 0.019 placebo L @ 32wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
-0.002 vs -0.061 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.086 vs 0.028 placebo L @ 40wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.133 vs -0.007 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.15 vs -0.037 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.149 vs -0.02 placebo L @ 1wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.149 vs 0 placebo L @ 2wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.146 vs -0.026 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.132 vs -0.015 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.125 vs -0.005 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.085 vs -0.03 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.102 vs -0.028 placebo L @ 18wk5 mcg qd
NCT00782210 · Phase 3
0.055 vs -0.028 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.065 vs -0.026 placebo L @ 32wk5 mcg qd
NCT00782210 · Phase 3
0.087 vs -0.044 placebo L @ 40wk5 mcg qd
NCT00782210 · Phase 3
0.011 vs -0.083 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.113 vs 0.054 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.122 vs 0.029 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.075 vs 0.043 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.114 vs 0.064 placebo L @ 18wk5 mcg qd
NCT00782509 · Phase 3
0.066 vs 0.021 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.099 vs 0.061 placebo L @ 32wk5 mcg qd
NCT00782509 · Phase 3
0.104 vs 0.062 placebo L @ 40wk5 mcg qd
NCT00782509 · Phase 3
0.038 vs -0.008 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.118 vs 0.03 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.113 vs -0.014 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.062 vs -0.041 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.084 vs -0.014 placebo L @ 18wk5 mcg qd
NCT00796653 · Phase 3
0.023 vs -0.044 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.081 vs -0.007 placebo L @ 32wk5 mcg qd
NCT00796653 · Phase 3
0.071 vs -0.016 placebo L @ 40wk5 mcg qd
NCT00796653 · Phase 3
0.012 vs -0.069 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.244 vs 0.025 placebo L @ 12wk5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.231 vs -0.021 placebo L @ 12wk5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.276 vs 0.213 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.103 vs -0.082 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.243 vs -0.001 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.11 vs 0.042 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.065 vs -0.046 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.079 vs -0.018 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.066 vs 0.06 placebo L @ 18wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.038 vs -0.018 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.08 vs 0.019 placebo L @ 32wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.022 vs -0.061 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.087 vs 0.028 placebo L @ 40wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.125 vs -0.007 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.154 vs -0.037 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.154 vs -0.02 placebo L @ 1wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.171 vs 0 placebo L @ 2wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.136 vs -0.026 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.233 vs 0.025 placebo L @ 12wk2.5 μg + 5 μg
NCT01964352 · Phase 3 · registry result, not featured evidence · combination
0.284 vs -0.021 placebo L @ 12wk2.5 μg + 5 μg
NCT02006732 · Phase 3 · registry result, not featured evidence · combination
0.151 vs -0.02 placebo L @ 1wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.148 vs 0 placebo L @ 2wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.153 vs -0.026 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.269 vs 0.235 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.154 vs -0.037 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.09 vs -0.02 placebo L @ 1wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.09 vs 0 placebo L @ 2wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.068 vs -0.026 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FVC Peak 0.546 vs 0.245 placebo L @ 0wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 58 more results
0.499 vs 0.207 placebo L @ 2wk10 mcg qd
NCT00782210 · Phase 3
0.46 vs 0.18 placebo L @ 6wk10 mcg qd
NCT00782210 · Phase 3
0.43 vs 0.169 placebo L @ 12wk10 mcg qd
NCT00782210 · Phase 3
0.42 vs 0.188 placebo L @ 24wk10 mcg qd
NCT00782210 · Phase 3
0.369 vs 0.109 placebo L @ 48wk10 mcg qd
NCT00782210 · Phase 3
0.535 vs 0.202 placebo L @ 0wk10 mcg qd
NCT00782509 · Phase 3
0.464 vs 0.254 placebo L @ 2wk10 mcg qd
NCT00782509 · Phase 3
0.434 vs 0.183 placebo L @ 6wk10 mcg qd
NCT00782509 · Phase 3
0.422 vs 0.213 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.429 vs 0.223 placebo L @ 24wk10 mcg qd
NCT00782509 · Phase 3
0.419 vs 0.208 placebo L @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.476 vs 0.247 placebo L @ 2wk10 mcg qd
NCT00796653 · Phase 3
0.417 vs 0.196 placebo L @ 6wk10 mcg qd
NCT00796653 · Phase 3
0.396 vs 0.171 placebo L @ 12wk10 mcg qd
NCT00796653 · Phase 3
0.369 vs 0.189 placebo L @ 24wk10 mcg qd
NCT00796653 · Phase 3
0.352 vs 0.137 placebo L @ 48wk10 mcg qd
NCT00796653 · Phase 3
0.383 vs 0.086 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.537 vs 0.191 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.474 vs 0.268 placebo L @ 2wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.433 vs 0.202 placebo L @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.432 vs 0.194 placebo L @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.414 vs 0.207 placebo L @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.371 vs 0.193 placebo L @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.44 vs 0.138 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.335 vs 0.109 placebo L @ 4wk10mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.449 vs 0.152 placebo L @ 4wk10 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.509 vs 0.245 placebo L @ 0wk5 mcg qd
NCT00782210 · Phase 3
0.471 vs 0.207 placebo L @ 2wk5 mcg qd
NCT00782210 · Phase 3
0.43 vs 0.18 placebo L @ 6wk5 mcg qd
NCT00782210 · Phase 3
0.421 vs 0.169 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.419 vs 0.188 placebo L @ 24wk5 mcg qd
NCT00782210 · Phase 3
0.356 vs 0.109 placebo L @ 48wk5 mcg qd
NCT00782210 · Phase 3
0.534 vs 0.202 placebo L @ 0wk5 mcg qd
NCT00782509 · Phase 3
0.479 vs 0.254 placebo L @ 2wk5 mcg qd
NCT00782509 · Phase 3
0.451 vs 0.183 placebo L @ 6wk5 mcg qd
NCT00782509 · Phase 3
0.439 vs 0.213 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.449 vs 0.223 placebo L @ 24wk5 mcg qd
NCT00782509 · Phase 3
0.415 vs 0.208 placebo L @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.48 vs 0.247 placebo L @ 2wk5 mcg qd
NCT00796653 · Phase 3
0.443 vs 0.196 placebo L @ 6wk5 mcg qd
NCT00796653 · Phase 3
0.386 vs 0.171 placebo L @ 12wk5 mcg qd
NCT00796653 · Phase 3
0.371 vs 0.189 placebo L @ 24wk5 mcg qd
NCT00796653 · Phase 3
0.325 vs 0.137 placebo L @ 48wk5 mcg qd
NCT00796653 · Phase 3
0.586 vs 0.433 Placebo and Tiotropium L @ 12wk5µg olodaterol + 18µg tiotropium
NCT01694771 · Phase 3 · registry result, not featured evidence
0.386 vs 0.086 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.526 vs 0.191 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.454 vs 0.268 placebo L @ 2wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.411 vs 0.202 placebo L @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.382 vs 0.194 placebo L @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.379 vs 0.207 placebo L @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.344 vs 0.193 placebo L @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
0.436 vs 0.138 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.351 vs 0.109 placebo L @ 4wk5mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.432 vs 0.152 placebo L @ 4wk5 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.438 vs 0.152 placebo L @ 4wk20 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
0.562 vs 0.457 placebo L @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.362 vs 0.109 placebo L @ 4wk2mcg
NCT00824382 · Phase 2 · registry result, not featured evidence
0.44 vs 0.152 placebo L @ 4wk2 mcg qd
NCT00452400 · Phase 2 · registry result, not featured evidence
FVC AUC(0-12h 0.23 vs -0.019 placebo L @ 12wk10 mcg qd
absolute change · L
NCT00782210 · Phase 3
show 9 more results
0.212 vs 0.057 placebo L @ 12wk10 mcg qd
NCT00782509 · Phase 3
0.192 vs -0.11 placebo L @ 6wk10 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.321 vs -0.006 placebo L @ 6wk10 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.214 vs -0.032 placebo L @ 6wk10 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
0.283 vs -0.019 placebo L @ 12wk5 mcg qd
NCT00782210 · Phase 3
0.199 vs 0.057 placebo L @ 12wk5 mcg qd
NCT00782509 · Phase 3
0.172 vs -0.11 placebo L @ 6wk5 mcg qd
NCT01040689 · Phase 3 · registry result, not featured evidence
0.324 vs -0.006 placebo L @ 6wk5 mcg qd
NCT01040728 · Phase 3 · registry result, not featured evidence
0.219 vs -0.032 placebo L @ 6wk5 mcg qd
NCT00932646 · Phase 3 · registry result, not featured evidence
PEF Weekly Avg Morning 195.475 vs 180.019 placebo L/min10 mcg qd
absolute value · L/min
NCT00782210 · Phase 3
show 15 more results
203.873 vs 182.939 placebo L/min10 mcg qd
NCT00782509 · Phase 3
193.376 vs 180.019 placebo L/min5 mcg qd
NCT00782210 · Phase 3
196.3 vs 182.939 placebo L/min5 mcg qd
NCT00782509 · Phase 3
248.76 vs 227.81 Tiotropium L/min @ 1wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
247.77 vs 228.57 Tiotropium L/min @ 2wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
248.33 vs 228.82 Tiotropium L/min @ 3wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
247.3 vs 226.49 Tiotropium L/min @ 4wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
244.43 vs 227.81 Tiotropium L/min @ 1wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
248.84 vs 227.81 Tiotropium L/min @ 1wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
240.87 vs 228.57 Tiotropium L/min @ 2wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.99 vs 228.57 Tiotropium L/min @ 2wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
239.61 vs 228.82 Tiotropium L/min @ 3wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.39 vs 228.82 Tiotropium L/min @ 3wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
234.14 vs 226.49 Tiotropium L/min @ 4wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
249.17 vs 226.49 Tiotropium L/min @ 4wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
PEF Weekly Avg Evening 205.236 vs 190.676 placebo L/min10 mcg qd
absolute value · L/min
NCT00782210 · Phase 3
show 15 more results
216.155 vs 195.502 placebo L/min10 mcg qd
NCT00782509 · Phase 3
207.862 vs 190.676 placebo L/min5 mcg qd
NCT00782210 · Phase 3
207.958 vs 195.502 placebo L/min5 mcg qd
NCT00782509 · Phase 3
268.58 vs 249.1 Tiotropium L/min @ 1wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
266.4 vs 247.1 Tiotropium L/min @ 2wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
265.67 vs 249.78 Tiotropium L/min @ 3wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
265.5 vs 246.77 Tiotropium L/min @ 4wk5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
260.86 vs 249.1 Tiotropium L/min @ 1wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
267.47 vs 249.1 Tiotropium L/min @ 1wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
260.73 vs 247.1 Tiotropium L/min @ 2wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
267.31 vs 247.1 Tiotropium L/min @ 2wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
258.2 vs 249.78 Tiotropium L/min @ 3wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
268.16 vs 249.78 Tiotropium L/min @ 3wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
253.12 vs 246.77 Tiotropium L/min @ 4wk5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
266.61 vs 246.77 Tiotropium L/min @ 4wk5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Daytime Rescue Puffs Daily Avg 0.839 vs 1.487 placebo count10 mcg qd
event count · count
NCT00782210 · Phase 3
show 15 more results
0.85 vs 1.363 placebo count @ 48wk10 mcg qd
NCT00782509 · Phase 3
0.967 vs 1.487 placebo count5 mcg qd
NCT00782210 · Phase 3
0.947 vs 1.363 placebo count @ 48wk5 mcg qd
NCT00782509 · Phase 3
0.406 vs 0.437 placebo count @ 1wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.421 vs 0.466 placebo count @ 2wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.407 vs 0.459 placebo count @ 3wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.408 vs 0.479 placebo count @ 4wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.375 vs 0.479 placebo count @ 5wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.378 vs 0.491 placebo count @ 6wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.403 vs 0.499 placebo count @ 7wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.417 vs 0.482 placebo count @ 8wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.396 vs 0.487 placebo count @ 9wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.392 vs 0.48 placebo count @ 10wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.383 vs 0.482 placebo count @ 11wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
0.393 vs 0.483 placebo count @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
Nighttime Rescue Puffs Daily Avg 1.492 vs 2.283 placebo count10 mcg qd
event count · count
NCT00782210 · Phase 3
show 15 more results
1.312 vs 2.072 placebo count @ 48wk10 mcg qd
NCT00782509 · Phase 3
1.701 vs 2.283 placebo count5 mcg qd
NCT00782210 · Phase 3
1.652 vs 2.072 placebo count @ 48wk5 mcg qd
NCT00782509 · Phase 3
1.222 vs 1.633 placebo count @ 1wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.232 vs 1.677 placebo count @ 2wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.229 vs 1.707 placebo count @ 3wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.239 vs 1.709 placebo count @ 4wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.177 vs 1.71 placebo count @ 5wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.148 vs 1.692 placebo count @ 6wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.139 vs 1.641 placebo count @ 7wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.173 vs 1.628 placebo count @ 8wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.125 vs 1.636 placebo count @ 9wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.108 vs 1.63 placebo count @ 10wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.104 vs 1.63 placebo count @ 11wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
1.143 vs 1.625 placebo count @ 12wk5 μg and 18 μg
NCT01696058 · Phase 3 · registry result, not featured evidence · combination
Patient Global Assessment 3 vs 3.5 placebo score @ 6wk10 mcg qd
absolute value · score
NCT00782210 · Phase 3
show 31 more results
3 vs 3.4 placebo score @ 12wk10 mcg qd
NCT00782210 · Phase 3
3 vs 3.5 placebo score @ 24wk10 mcg qd
NCT00782210 · Phase 3
3.1 vs 3.4 placebo score @ 48wk10 mcg qd
NCT00782210 · Phase 3
2.9 vs 3.3 placebo score @ 6wk10 mcg qd
NCT00782509 · Phase 3
3 vs 3.2 placebo score @ 12wk10 mcg qd
NCT00782509 · Phase 3
2.9 vs 3.3 placebo score @ 24wk10 mcg qd
NCT00782509 · Phase 3
3 vs 3.3 placebo score @ 48wk10 mcg qd
NCT00782509 · Phase 3
3.2 vs 3.4 placebo score @ 6wk10 mcg qd
NCT00796653 · Phase 3
3 vs 3.3 placebo score @ 12wk10 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 24wk10 mcg qd
NCT00796653 · Phase 3
3 vs 3.2 placebo score @ 48wk10 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.4 placebo score @ 6wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.3 placebo score @ 12wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 24wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 48wk10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.5 placebo score @ 6wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.4 placebo score @ 12wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.5 placebo score @ 24wk5 mcg qd
NCT00782210 · Phase 3
3.1 vs 3.4 placebo score @ 48wk5 mcg qd
NCT00782210 · Phase 3
3 vs 3.3 placebo score @ 6wk5 mcg qd
NCT00782509 · Phase 3
2.9 vs 3.2 placebo score @ 12wk5 mcg qd
NCT00782509 · Phase 3
3 vs 3.3 placebo score @ 24wk5 mcg qd
NCT00782509 · Phase 3
3.1 vs 3.3 placebo score @ 48wk5 mcg qd
NCT00782509 · Phase 3
3.1 vs 3.4 placebo score @ 6wk5 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 12wk5 mcg qd
NCT00796653 · Phase 3
3.1 vs 3.3 placebo score @ 24wk5 mcg qd
NCT00796653 · Phase 3
3.2 vs 3.2 placebo score @ 48wk5 mcg qd
NCT00796653 · Phase 3
3 vs 3.4 placebo score @ 6wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.3 placebo score @ 12wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
2.9 vs 3.1 placebo score @ 24wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
3 vs 3.1 placebo score @ 48wk5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence
Time to Exacerbation 7.85 vs 6.37 placebo months10 mcg qd
time to event · months
NCT00782210 · Phase 3 · converted to months from 239 days as posted
show 11 more results
7.2 vs 10.05 placebo months*10 mcg qd
NCT00782509 · Phase 3 · converted to months from 219 days as posted
7.1 vs 10.05 placebo months*10 mcg qd
NCT00782509 · Phase 3 · converted to months from 216 days as posted
6.87 vs 4.7 placebo months*10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence · converted to months from 209 days as posted
7.75 vs 6.37 placebo months*5 mcg qd
NCT00782210 · Phase 3 · converted to months from 236 days as posted
7.39 vs 10.05 placebo months*5 mcg qd
NCT00782509 · Phase 3 · converted to months from 225 days as posted
10.35 vs 10.05 placebo months*5 mcg qd
NCT00782509 · Phase 3 · converted to months from 315 days as posted
6.21 vs 4.7 placebo months*5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence · converted to months from 189 days as posted
5.49 vs 6.37 placebo months*10 mcg qd + tiotropium
NCT00782210 · Phase 3 · combination · converted to months from 167 days as posted
4.4 vs 4.7 placebo months*10 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence · combination · converted to months from 134 days as posted
6.67 vs 6.37 placebo months*5 mcg qd + tiotropium
NCT00782210 · Phase 3 · combination · converted to months from 203 days as posted
4.47 vs 4.7 placebo months*5 mcg qd
NCT00793624 · Phase 3 · registry result, not featured evidence · combination · converted to months from 136 days as posted

+ 93 further endpoints in the CSV export.

Umeclidinium/Vilanterol

FEV1 Wm0 6 h 0.276 vs 0.17 TIO L @ 24wk62.5/25 µg
absolute change · L
NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 71.7% (n=173) vs 53.8% (n=171) UMEC @ 0wk62.5/25 µg once daily
responder rate · % of participants
NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 · converted to % from 124 participants as posted
show 1 more result
51% (n=202) vs 40.1% (n=202) UMEC @ 0.14wk*62.5/25 µg
Responder
NCT02014480 · Phase 3 · registry result, not featured evidence · converted to % from 103 participants as posted
FEV1 Change 3 h 0.164 vs 0.091 Tiotropium Bromide L @ 12wk62.5/25 µg
absolute change · L
NCT01899742 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olodaterol's landscape · Umeclidinium/Vilanterol's landscape